New Data for Bispecific Antibody Epcoritamab (DuoBody ® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

- Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th American Society of Hematology (ASH) congress - Follicular lymphoma is the second most common...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TDS FVT TRI Source Type: news